Jiang M, Bennani NN, Feldman AL (2017) Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol 10:239–249. https://doi.org/10.1080/17474086.2017.1281122

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P (2021) Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel). https://doi.org/10.3390/medsci9010005

Article  Google Scholar 

Collaboration; GBoDC, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3:524–548. https://doi.org/10.1001/jamaoncol.2016.5688

Article  Google Scholar 

Ansell SM (2018) Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 93:704–715. https://doi.org/10.1002/ajh.25071

Article  PubMed  Google Scholar 

Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE et al (2016) ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther 15:2709–2721. https://doi.org/10.1158/1535-7163.MCT-16-0233

Article  CAS  PubMed  Google Scholar 

Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A et al (2021) Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol 8:e433–e445. https://doi.org/10.1016/S2352-3026(21)00103-4

Article  PubMed  PubMed Central  Google Scholar 

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068. https://doi.org/10.1200/JCO.2013.54.8800

Article  PubMed  PubMed Central  Google Scholar 

Food and Drug Administration (1999) Guidance for industry: population pharmacokinetics. http://www.fda.gov/downloads/drugs/guidances/UCM072137.pdf. Accessed 21 Feb 2022

Food and Drug Administration (2003) Guidance for industry: exposure response relationships. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf. Accessed 21 Feb 2022

European Medicines Agency (2007) Committee for medicinal products for human use (CHMP). Guideline on reporting the results of poulation pharmacokinetic analyses. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf. Accessed 2 Feb 2022

Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T et al (2012) Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol 91:705–714. https://doi.org/10.1007/s00277-011-1363-4

Article  CAS  PubMed  Google Scholar 

Gupta M, Stenson M, O’Byrne M, Maurer MJ, Habermann T, Cerhan JR et al (2016) Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Ralpha as predictors of event-free survival in T-cell lymphoma. Ann Oncol 27:165–172. https://doi.org/10.1093/annonc/mdv486

Article  CAS  PubMed  Google Scholar 

Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Stromberg U, Loskog AS (2010) T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 131:371–376. https://doi.org/10.1111/j.1365-2567.2010.03308.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Liao DZ, Zhang J, Xia ZJ, Peng XW, Lu Y (2013) Clinical significance of serum soluble interleukin-2 receptor-alpha in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. Med Oncol 30:723. https://doi.org/10.1007/s12032-013-0723-4

Article  CAS  PubMed  Google Scholar 

Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ et al (2012) Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the Everest trial. Eur J Heart Fail 14:302–311. https://doi.org/10.1093/eurjhf/hfs007

Article  CAS  PubMed  Google Scholar 

Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: a guide for clinicians. CMAJ 172:367–379. https://doi.org/10.1503/cmaj.1040752

Article  PubMed  PubMed Central  Google Scholar 

Herrera A, Carlo-Stella C, Collins G, Maddocks K, Bartlett N, Savage K et al (2020) Preliminary results of a phase 2 study of camidanlumab tesirine (Cami), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory Hodgkin lymphoma. Blood 136:21–23. https://doi.org/10.1182/blood-2020-137451

Article  Google Scholar 

clinicaltrials.gov Study to evaluate the efficacy and safety of camidanlumab tesirine (ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (NCT04052997). https://clinicaltrials.gov/ct2/show/NCT04052997. Accessed 5 Jan 2022

Toukam M, Wuerthner J, Havenith K, Hamadani M, Caimi PF, Kopotsha T et al. Population pharmacokinetics analysis of Camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-022-04486-4